Clinical trials: Dermatitis Eczema
Atopic Dermatitis
Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis
To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD).
- Trial name
- NCT02456480
- Testing
- CLS001, Vehicle
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- Maruho Co., Ltd.
Atopic Dermatitis
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
The main purpose of this trial is to investigate what happens to the trial drug in the body and to confirm that it is safe to use and effective for treating atopic dermatitis (AD) in children.
- Trial name
- NCT05388760
- Testing
- Tralokinumab
- Where
- 11 sites in Czechia, France and 3 more
- Volunteers
- 28 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled…
- Trial name
- NCT07054736
- Testing
- XKH001 Injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Atopic Dermatitis
Jaktinib Hydrochloride Cream For Atopic Dermatitis
This study includes a dose escalation part and a dose extension part.
- Trial name
- NCT04435392
- Testing
- Jaktinib Hydrochloride Cream
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Dermatitis, Atopic
Protopic Ointment in Children Atopic Eczema
Children with atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks. They could continue during 3 more weeks once a day if needed.
- Trial name
- NCT00689832
- Testing
- Tacrolimus 0.03%, Fluticasone 0.005%
- Where
- France
- Volunteers
- 487 people
- Sponsor
- Astellas Pharma Inc
Dermatitis, Atopic, Dermatitis
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- ADhere-J (NCT04760314)
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 37 sites in Japan
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis
The purpose of this study is to determine the safety and efficacy of three concentrations of ZK 245186 ointment and vehicle on increasing body surface areas for the treatment of atopic dermatitis and to obtain dose-response…
- Trial name
- NCT00944632
- Testing
- ZK 245186
- Where
- 3 sites in South Africa
- Volunteers
- 64 people
- Sponsor
- Bayer
Atopic Dermatitis, Pruritus
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis.
- Trial name
- NCT04490109
- Testing
- B244, Vehicle
- Where
- 56 sites in United States
- Volunteers
- 547 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
Evalution the Safety and Efficacy in Atopic Dermatitis Patients
A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year results from the K0102 extension study
- Trial name
- NCT03962387
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Dermatitis, Atopic
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts.
- Trial name
- NCT03750643
- Testing
- LY3454738
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis
Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3%…
- Trial name
- NCT03250624
- Testing
- CD5024 0.3% cream
- Where
- 5 sites in Canada
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis
The purpose of this study is to estimate the systemic exposure to tacrolimus in infants with atopic dermatitis after repeated application of tacrolimus ointment.
- Trial name
- NCT00535691
- Testing
- Tacrolimus Ointment 0.03%
- Where
- 8 sites in Canada, Finland and 3 more
- Volunteers
- 53 people
- Sponsor
- Astellas Pharma Inc
Dermatitis, Atopic
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy and safety of 611 in chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT05544591
- Testing
- 611 Q2W, 611 Q4W
- Where
- 5 sites in China
- Volunteers
- 93 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.
- Trial name
- NCT06767540
- Where
- 28 sites in China
- Volunteers
- 198 people
- Sponsor
- Akeso
Hand Dermatoses
Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis
The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.
- Trial name
- TAC-202 (NCT00890968)
- Testing
- Triamcinolone Acetonide (TAC) DuraPeel
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- ZARS Pharma Inc.
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
A unicentric, blind, non-comparative clinical study to evaluate the efficacy of a moisturizer in reducing clinical symptons of atopic dermatites in children through clinical, subjective and instrumental evaluations.
- Trial name
- NCT05530707
- Testing
- Moisturizer containing saccharide isomerate and niacinamide
- Where
- Brazil
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Farmoquimica S.A.
Atopic Dermatitis
The Effect of Nature-based Exposure on the Immune System and Skin Health of Atopic Dermatitis Patients.
The purpose of the study is to explore the effect of nature-based exposure on immunological biomarkers and the condition and symptoms of atopic skin.
- Trial name
- NCT06129136
- Testing
- Nature-based exposure by biodiversity component in lotion.
- Where
- Finland
- Volunteers
- 142 people
- Sponsor
- Uute Scientific Oy
Dermatitis, Atopic
Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis
The study shall explore whether treatment of atopic dermatitis is equally effective with respect to a marketed medical device and a new medical device.
- Trial name
- Phoenix II (NCT01948869)
- Testing
- Phoenix II (BAY81-2996), Phoenix I (BAY81-2996)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Bayer
Dermatitis, Atopic
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05391061
- Testing
- Abrocitinib
- Where
- South Korea
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.